Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • Interferon- and ribavirin-free DAA regimens recommended for the treatment of HCV infection in patients coinfected with HIV have shown to be highly tolerable with generally favorable safety profiles
  • The most important safety consideration for HCV therapy in patients with HCV/HIV coinfection are established and potential drug–drug interactions between HCV DAAs and antiretroviral agents

Action required